Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 6,414 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 6,414 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the transaction, the insider owned 183,275 shares in the company, valued at $1,550,506.50. This represents a 3.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Kura Oncology Trading Down 5.1%

Kura Oncology stock opened at $8.04 on Thursday. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $12.49. The company’s fifty day moving average price is $10.26 and its two-hundred day moving average price is $9.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The company has a market capitalization of $699.64 million, a price-to-earnings ratio of -3.24 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its stake in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after acquiring an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the period. Brevan Howard Capital Management LP bought a new position in Kura Oncology in the second quarter valued at approximately $80,000. Finally, Merit Financial Group LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at $89,000.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Neutral Sentiment: Recent analyst activity is mixed — several firms (JMP, Leerink, HC Wainwright) maintain positive ratings and high price targets while others (Zacks, Weiss) issued negative views. The consensus remains a “Moderate Buy” but with divergent opinions that can sustain volatility for the stock. Analyst Coverage Summary
• Neutral Sentiment: Institutions hold large positions and some have increased stakes (Vanguard, EcoR1, Jacobs Levy, Geode, Qube Research). Significant institutional ownership can cushion price moves, though it also means bigger blocks could trade. Institutional Holdings Detail
• Negative Sentiment: Multiple insider sales reported on Jan. 27–28: SVP Teresa Brophy Bair sold 11,208 shares; Mollie Leoni sold 8,180; Thomas J. Doyle (SVP) sold 7,142; Brian T. Powl sold 6,414; COO Kathleen Ford sold 1,813; and Francis Burrows sold 1,311 — all at about $8.46 per share. The cluster of executive sales (reductions of ~1–4.7% of post-trade holdings for each insider) is weighing on sentiment because coordinated or same‑day sales by multiple insiders often trigger investor concern about near-term outlook or liquidity needs. Insider Trades Report

Wall Street Analyst Weigh In

Several brokerages have weighed in on KURA. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 20th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a research note on Friday, November 14th. JMP Securities restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.